A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. An interchangeable biosimilar is a biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable biosimilar medications. An interchangeable biosimilar product may be substituted for the original product without consulting the prescriber, much like how generic drugs are routinely substituted for brand name drugs.

The global Biosimilar and Interchangeable Biologics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Biosimilar and Interchangeable Biologics Industry Forecast” looks at past sales and reviews total world Biosimilar and Interchangeable Biologics sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar and Interchangeable Biologics sales for 2023 through 2029.

This Insight Report provides a comprehensive analysis of the global Biosimilar and Interchangeable Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyses the strategies of leading global companies with a focus on Biosimilar and Interchangeable Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar and Interchangeable Biologics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and Interchangeable Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar and Interchangeable Biologics.

United States market for Biosimilar and Interchangeable Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Biosimilar and Interchangeable Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Biosimilar and Interchangeable Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Biosimilar and Interchangeable Biologics players cover Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar and Interchangeable Biologics market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Monoclonal Antibodies
• Interferon
• Insulin
• Vaccines
• Others

Segmentation by Application:

• Hospital
• Retail Pharmacy
• Other

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Roche
• Amgen
• AbbVie
• Sanofi
• Johnson & Johnson
• Pfizer
• Novo Nordisk
• Eli Lilly
• Novartis
• Merck
• Biogen
• Celltrion
• Sobi
• 3SBIO
• Changchun High Tech
• Kanghong Pharma
• Innovent Biologics
• Gan&Lee
• Tonghua Dongbao
• United Laboratory